This meta-analysis concluded similar efficacy of currently available long-acting insulin (insulin degludec and glargine) in T2DM patients in the Asian region, with lower hypoglycemia episodes with insulin glargine. The gene discussed is INS; the disease is type 2 diabetes mellitus.